A triterpenoid cyclase and its application
The identification of the ailanthus-type 6-6-5 ring triterpenoid cyclase AmAS through gene mining and heterologous expression in yeast cells has solved the problems of scarce natural resources and difficult chemical synthesis of ailanthus-type triterpenoid compounds, and has enabled the provision of molecules for efficient biosynthesis and new drug development.
Patent Information
- Application Number
- CN202310614802.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-05-26
AI Technical Summary
In the existing technology, there are few natural resources of ailanthus-type 6-6-5 cyclic triterpenoids, which are difficult to synthesize chemically, and there is very little research on the cyclases responsible for their biosynthesis, which limits their large-scale application.
The ailanthus-type 6-6-5 ring triterpenoid cyclase AmAS was identified through gene mining and heterologous expression in yeast cells. Its amino acid sequence and nucleic acid molecule were provided, and its catalytic function was realized through recombinant expression vectors and engineered microorganisms for biosynthesis.
This method enables the efficient synthesis of ailanthus triterpenoids, avoiding the drawbacks of chemical synthesis, providing structurally diverse new drug development molecules, and reducing the difficulty of extraction and separation.
Smart Images

Figure QLYQS_1 
Figure BDA0004253523390000031 
Figure BDA0004253523390000041
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to a novel triterpenoid cyclase derived from Astragalus mongholicus of the legume family and its applications. Background Technology
[0002] Triterpenes are a class of compounds with a wide range of biological and pharmacological activities. The most widely distributed triterpenes in plants are tetracyclic and pentacyclic triterpenes, while ailanthus-type 6-6-5-cyclic triterpenes are relatively rare. To date, more than 50 species of *Ailanthus altissima* and its ailanthus glycosides have been reported in plants (Domingo, V.; Arteaga, JF; Quílez Del Moral, JF; Barrero, A.F. *Unusually Cyclized Triterpenes: Occurrence, Biosynthesis and Chemical Synthesis*. *Nat. Prod. Rep.* 2009, 26, 115–134. Stonik, VA; Kolesnikova, S. *A. A. *A ...
[0003] The complex structure and synthesis of triterpenes result in low concentrations in plants, making extraction and separation difficult and limiting their large-scale application. Utilizing biotechnology to elucidate the biosynthetic pathways of triterpenes can effectively increase the content of target metabolites, or synthetic biology methods can be used to reconstruct the biosynthetic pathways in vitro to produce triterpenes. Oxidosqualene cyclases are the main enzymes involved in triterpenoid formation, catalyzing the formation of different types of triterpenoid skeletons from the precursor 2,3-epoxysqualene. To date, more than 170 cyclases have been functionally identified in plants, most of which are cycloartenol synthases responsible for synthesizing tetracyclic triterpenes, lupeol synthases for pentacyclic triterpenes, and β-amyrin synthases (Wang, J.; Guo, Y.; Yin, X.; Wang, X.; Qi, X.; Xue, Z. Diverse Triterpene Skeletons Are Derived from The Expansion and Divergent Evolution of 2,3-Oxidosqualene Cyclases in Plants. Crit. Rev. Biochem. Mol. 2022, 57, 113–132. Thimmappa, R.; Geisler, K.; Louveau, T.; O'Maille, P.; Osbourn, A. Triterpene Biosynthesis in Plants. Annu. Rev. Plant Biol.2014.65,225–257.Tao,H.;Lauterbach,L.;Bian,G.;Chen,R.;Hou,A.;Mori,T.;Cheng,S.;Hu,B.;Lu,L.;Mu,X. ;Li,M.;Adachi,N.;Kawasaki,M.;Moriya,T.;Senda,T.;Wang,X.;Deng,Z.;Abe,I.;Dickschat,JS;Liu,T.Discovery ofNon-Squalene Triterpenes. Nature, 2022, 606, 414–419.).However, there are few reports on cyclases responsible for the synthesis of tricyclic triterpenoids. Currently, only two cyclases, AtPEN1 and AtPEN4, from the plant Arabidopsis thaliana have been reported (Xiang, T.; Shibuya, M.; Katsube, Y.; Tsutsumi, T.; Otsuka, M.; Zhang, H.; Masuda, K.; Ebizuka, YA. New Triterpene Synthase from Arabidopsisthaliana Produces a Tricyclic Triterpene with Two HydroxylGroups. Org. Lett. 2006, 8, 2835–2838. Fazio, GC; Xu, R.; Matsuda, SPT. Genome Mining to Identify New Plant Triterpenoids. J. Am. Chem. Soc. 2004, 126, 5678–5679.).
[0004] In summary, current research on ailanthus-type 6-6-5 cyclic triterpenes and their analogues has the following limitations and shortcomings:
[0005] 1. Natural resources of ailanthus-type 6-6-5 ring triterpenoids are scarce, and their chemical synthesis is difficult;
[0006] 2. Research on the cyclases and their genes responsible for the biosynthesis of ailanthus-type 6-6-5 ring triterpenoid skeletons is very limited, especially in the application research of enzymatic synthesis of active ailanthus-type 6-6-5 ring triterpenoid compounds. Summary of the Invention
[0007] To overcome the shortcomings of existing technologies, this invention utilizes gene mining technology to identify and functionally characterize key cyclases in the biosynthetic pathway of ailanthus-type 6-6-5 ring triterpenes. These results lay the foundation, to some extent, for the elucidation of the complete biosynthetic pathway of ailanthus-type triterpenes and the creation of artificial pathways.
[0008] In a first aspect, the present invention provides a novel *Malabaricanes* 6-6-5 cyclic triterpenoid cyclase, AmAS, having the amino acid sequence shown in SEQ ID NO:1, or an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO:1 and possessing catalytic activity for the formation of triterpenoid compounds. The catalytic function of the *Malabaricanes* 6-6-5 cyclic triterpenoid cyclase (AmAS) provided by the present invention can be identified through gene mining and heterologous expression in yeast cells.
[0009] Secondly, the present invention provides a nucleic acid molecule encoding the aforementioned triterpenoid cyclase AmAS. Preferably, the nucleic acid sequence of the nucleic acid molecule is as shown in SEQ ID NO.2, or has more than 90% homology with the sequence shown in SEQ ID No.2. This nucleic acid molecule can be cloned from plants of the genus Astragalus, such as Astragalus membranaceus and Astragalus mongholicus.
[0010] Thirdly, the present invention provides a recombinant expression vector comprising the nucleic acid molecule.
[0011] Fourthly, the present invention provides engineered microorganisms comprising the nucleic acid molecule or the recombinant expression vector.
[0012] Fifthly, the present invention provides the application of the triterpenoid cyclase, the nucleic acid molecule, the recombinant expression vector, or the engineered microorganism in the production of ailanthus-type 6-6-5 cyclic triterpenes.
[0013] As a preferred embodiment of the present invention, the ailanthus-type 6-6-5-cyclic triterpenoid has a structure as shown in Formula 1 or Formula 2:
[0014]
[0015] In a sixth aspect, the present invention provides a mutant of the triterpenoid cyclase.
[0016] As a specific embodiment, the mutant triterpenoid cyclase provided by this invention has the amino acid sequence shown in SEQ ID NO.1, and the 256th amino acid Q in this sequence is mutated to L or W (named AmAS-L / W). In a specific example, the catalytic activity of the AmAS-L / W mutant was analyzed by amino acid substitution amplification and heterologous expression in yeast cells.
[0017] As a specific embodiment, the mutant triterpenoid cyclase provided by this invention has the amino acid sequence shown in SEQ ID NO.1, and the 258th amino acid Y in this sequence is mutated to A or H (named AmAS-A / H). In a specific example, the catalytic activity of the AmAS-A / H mutant was analyzed by amino acid substitution amplification and heterologous expression in yeast cells.
[0018] As a specific embodiment, the mutant triterpenoid cyclase provided by this invention has the amino acid sequence shown in SEQ ID NO.1, with amino acid Q at position 256 mutated to L and amino acid Y at position 258 mutated to H (named AmAS-LH). In a specific example, the catalytic activity of the AmAS-LH mutant was analyzed by amino acid substitution amplification and heterologous expression in yeast cells.
[0019] As a specific embodiment, the mutant triterpenoid cyclase provided by this invention has the amino acid sequence shown in SEQ ID NO.1, and amino acids IIH at positions 725-727 of this sequence are mutated to VFM (named AmAS-VFM). In a specific example, the catalytic activity of the AmAS-VFM mutant was analyzed by amino acid substitution amplification and heterologous expression in yeast cells.
[0020] As a specific embodiment, the mutant triterpenoid cyclase provided by this invention has the amino acid sequence shown in SEQ ID NO.1, and amino acids 725-727 of this sequence are mutated at position IIH to VFN (named AmAS-VFN). In a specific example, the AmAS-VFN mutant can be used to alter substrate specificity and obtain different types of triterpenoids through amino acid substitution amplification and heterologous expression in yeast cells.
[0021] In a seventh aspect, the present invention provides a nucleic acid molecule encoding the mutated triterpenoid cyclase described in the sixth aspect.
[0022] Eighthly, the present invention provides a recombinant expression vector comprising the nucleic acid molecule described in the seventh aspect.
[0023] In a ninth aspect, the present invention provides engineered microorganisms comprising the nucleic acid molecule described in the seventh aspect or the recombinant expression vector described in the eighth aspect.
[0024] In a tenth aspect, the present invention provides the application of the aforementioned mutant triterpenoid cyclase, nucleic acid molecule, recombinant expression vector or engineered microorganism in the production of ailanthus-type 6-6-5 cyclic triterpenoids.
[0025] As a preferred embodiment of the present invention, the AmAS-VFN mutant produces ailanthus-type 6-6-5-cyclic triterpenes as shown in formulas 3, 4, 5, 6, or 7:
[0026]
[0027] Supplementary Explanation
[0028] Unless otherwise stated, the technical terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. This invention may also be practiced using any methods and materials similar to or equivalent to those described herein. While specific embodiments and preferred methods and materials are described herein, they do not impose any limitation on the invention.
[0029] Beneficial technical effects
[0030] The ailanthus-type 6-6-5-cyclic triterpenoid cyclase described in this invention can efficiently synthesize biosynthetic precursors of ailanthus-type triterpenoid compounds, avoiding the drawbacks of chemical synthesis methods such as poor stereoselectivity and regioselectivity, functional group protection and deprotection, long routes and high costs, and environmental pollution. Furthermore, it eliminates the need for extraction from plants, providing a novel method for obtaining ailanthus-type triterpenoid compounds. In addition, site-directed mutagenesis of this enzyme can yield structurally diverse triterpenoid compounds, providing new chemical entities for drug development. Attached Figure Description
[0031] Figure 1 GC-MS chromatograms of AmOSC2 fermentation products in yeast; (a) GC chromatogram of AmOSC2 fermentation products in yeast; (b) EI-MS chromatograms of compounds 1 and 2.
[0032] Figure 2 GC-MS spectra of fermentation products of AmAS site-directed mutant cyclase in yeast; (a) GC chromatograms of fermentation products of AmAS cyclase and its mutant in yeast, wherein (i) IIH725-727VFN, (ii) IIH725-727VFM, (iii) Q256W / Y258H, (iv) Q258H, (v) Q258A, (vi) Q256M, (vii) Q256L, (viii) wildtype; (b) EI-MS spectra of compound 3 and Lupeol standard.
[0033] Figure 3 MS spectra of fermentation products of AmAS site-directed mutant IIH725-727VFN in yeast; where (a) EI-MS spectrum of compound 4, (b) EI-MS spectrum of compound 5, (c) EI-MS spectrum of compound 6, and (d) EI-MS spectrum of compound 7. Detailed Implementation
[0034] The following specific embodiments are provided to further illustrate various aspects of the present invention. These embodiments are non-limiting and should not be construed as limiting any aspect of the invention. The scope of protection of the present invention is limited only by the claims. Various modifications and improvements can be made to various aspects of the present invention without departing from the scope of the claims, and these modifications and improvements also fall within the scope of protection of the present invention. For example, replacing the promoters and expression vectors used in the embodiments with other promoters and expression vectors commonly used in the art is something that those skilled in the art can understand and implement.
[0035] Additionally, it should be noted that, unless otherwise specified, all materials and reagents used in the following embodiments are commonly used in the art and can be obtained through conventional commercial means; all methods used are conventional methods known to those skilled in the art.
[0036] Example 1: Cloning of the AmAS gene
[0037] 1. Transcriptome sequencing and discovery of Ailanthus altissima-type 6-6-5 ring triterpenoid cyclases
[0038] Astragalus membranaceus was collected from the Medicinal Botanical Garden of Tiantan Park, Beijing. Fresh roots were taken for the experiment and rapidly frozen in liquid nitrogen, then stored at -80°C for later use. Transcriptome sequencing of fresh Astragalus membranaceus roots and data analysis of the raw data were commissioned to BGI Genomics. Based on the raw data analysis results, the AtPEN1 sequence reported in Arabidopsis thaliana was used as a probe to screen candidate genes for triterpenoid cyclases in Astragalus membranaceus that may be involved in the biosynthesis of Ailanthus altissima-type triterpenoid compounds using local BLAST. The ORF of the candidate genes was analyzed using Bioedit, and the physicochemical properties and transmembrane structures of the candidate genes were predicted using online servers such as ExPASy and TMHMM.
[0039] 2. Total RNA extraction and cDNA first-strand synthesis
[0040] Fresh roots of *Astragalus membranaceus* were used as the material for total RNA extraction. Total RNA was extracted according to the EZNATM Plant RNA Kit instructions. After extraction, the integrity of the total RNA was assessed by 0.8% non-deformed agarose gel electrophoresis, and the OD260 nm / OD280 nm ratio and RNA concentration were determined using a UV spectrophotometer. First-strand cDNA was synthesized using Transscript II First-Strand cDNA Synthesis Super Mix.
[0041] 3. Target gene amplification
[0042] (1) PCR reaction system: Based on the full-length information of the candidate genes obtained from screening, specific primers were designed to amplify the full-length candidate genes using cDNA as a template. The reaction system is shown in Table 1.
[0043] Table 1: PCR reaction system
[0044] reagents Volume (μL) Final concentration 10×KODBuffer 5 1× 2mMdNTPs 5 200μM <![CDATA[25mMMgSO4]]> 3 1.5mM 10μM Forward Primer 1 0.2μM 10μM Reverse Primer 1 0.2μM cDNA 1 >200ng KOD-Plus-Neo 1 1U <![CDATA[ddH2O]]> Supplement to 50
[0045] For candidate genes that do not contain complete ORFs, RACE primers (5′-RACE and / or 3′-RACE primers) were designed based on transcriptome sequence information. The 5′-end and / or 3′-end of the candidate gene were obtained by RACE-PCR, and then further spliced to obtain the full length of the candidate gene. Complete ORFs were predicted, and specific primers were designed to amplify the ORFs based on their upstream and downstream sequences. Sequencing verification was then performed. The RACE-PCR reaction system is shown in Table 2.
[0046] Table 2: PCR reaction system
[0047]
[0048]
[0049] (2) PCR reaction conditions (Touchdown): 94℃ pre-denaturation for 2 min; 98℃ denaturation for 10 s, initial setting 68℃ annealing for 30 s, annealing at a gradient of 0.5℃ per cycle, extension at 68℃ for 30 s / kb, for 36 cycles; 98℃ denaturation for 10 s, 50℃ annealing for 30 s, extension at 68℃ for 30 s / kb, for 15 cycles. After the last cycle, incubate at 68℃ for 5 min to allow the reaction mixture to fully amplify, then store at 4℃.
[0050] (3) PCR product detection, recovery, and sequencing verification: The PCR products were detected by agarose gel electrophoresis, and the products with the correct band size were excised and purified. Following the instructions, the purified PCR products were ligated with the cloning vector pEASY-Blunt and transformed into DH-5α competent E. coli cells. Positive clones were selected by blue-white screening and colony PCR for sequencing verification. Finally, the sequencing results were compared with the target gene sequence.
[0051] Example 2: Expression and Functional Identification of the AmAS Gene
[0052] 1. Construction of recombinant expression vectors
[0053] The candidate gene AmAS from Example 1 was used with a homologous recombination kit. II. The One Step Cloning Kit is used for constructing recombinant expression vectors. This kit utilizes the principle of homologous recombination. When designing PCR primers for key enzyme genes, a 15bp sequence is introduced at the 5′ end of each primer pair, identical to the sequences at both ends of a linearized vector (such as the pESC-His vector). This allows for directional cloning of the PCR product, eliminating the restriction of restriction enzyme sites during recombination. The PCR product does not require enzyme digestion or the use of ligase. The experimental procedure is shown below.
[0054] (1) Preparation of linearized empty vector: The pESC-His / Leu / Ura vector was digested with BamHI restriction enzyme according to the instructions, and the linear vector product was obtained by gel digestion.
[0055] (2) Preparation of PCR products (target gene): Add a 15bp base sequence homologous to the linearized vector to the 5′ end of each PCR primer (Table 3). Amplify the target gene containing the vector homologous arm using the synthesized primers with the vector homologous sequence, and recover the target gene fragment by gel excision.
[0056] Table 3: Specific primer sequences
[0057] Primer name Nucleic acid sequence (5' to 3') AmOSC2-pESC-His-F aggagaaaaaaccccATGTGGAAGTTGAAGATAGCAGAAG AmOSC2-pESC-His-R agtgagtcgtattacTTAAAGCCAAGTTGCGGCATTT
[0058] (3) Homologous recombination and transformation of linear vector and target gene fragment: Add each component to the homologous recombination reaction system shown in Table 4, mix gently, incubate in a PCR instrument at 37℃ for 30 min and immediately place on ice, transform the ligation product into Trans1-T1 competent cells, incubate on ice for 30 min, heat shock at 42℃ for 45 s, incubate on ice for 2 min, add 500 μL of LB medium, revive at 37℃ and 200 rpm for 1 h, take an appropriate amount of bacterial solution and spread it on solid LB medium containing ampicillin, incubate overnight, pick single colonies for colony PCR verification, select positive clones for sequencing to verify the correctness of inserting the target gene.
[0059] Table 4: Homologous recombination reactions
[0060] reagents Volume (μL) Linearized carrier X Target gene fragment Y 5xCEIIBuffer 2 Exnase II 1 <![CDATA[ddH2O]]> Add to 10 μL
[0061] Note: X / Y is calculated using the formula (the optimal amounts of linearized vector and insert fragment are 0.03 and 0.06 pmol, respectively).
[0062] 2. Construction of heterologous expression system for candidate triterpenoid cyclases
[0063] After the positive transformants, which were previously confirmed to be correct by sequencing, were cultured overnight in LB medium, recombinant plasmids containing the target gene (pESC-His-AmOSCs, pESC-Ura-tHMG1, and pESC-Leu-ERG7) were extracted using a kit. - The yeast transformation kit Frozen-EZYeast Transformation II™ was used to co-transform S. cerevisiae INVSc1. The cells were cultured on auxotrophic solid medium (SD-HLU), and plasmids were extracted. PCR was then used to verify the successful construction of the heterologous expression system. Simultaneously, pESC-His / pESC-Ura-tHMG1 / pESC-Leu-ERG7 were used.- Yeast S. cerevisiae INVSC1 was co-transformed as a negative control (IN-0) (Table 5).
[0064] Table 5: Plasmid composition of engineered yeast cells
[0065] strain name plasmid composition Control <![CDATA[pESC-His / pESC-Ura-tHMG1 / pESC-Leu-ERG7 - ]]> AmAS <![CDATA[pESC-His-AmAS / pESC-Ura-tHMG1 / pESC-Leu-ERG7 - ]]>
[0066] (1) Preparation of competent cells of Saccharomyces cerevisiae INVSc1
[0067] a. Activated S. cerevisiae INVSc1 cells were seeded into 10mLYPDA cells and cultured at 30℃ with shaking at 220rpm until the OD600 reached 0.8-1.0;
[0068] b. Collect cells by centrifugation at 500×g for 4 min at 4℃, and carefully discard the supernatant;
[0069] c. Add 10 ml of Frozen-EZYeast Solution 1, centrifuge at 500 × g for 4 min at 4 °C, and discard the supernatant;
[0070] d. Add 1 ml of FRozen-EZYeast Solution 2 and resuspend the cells;
[0071] e. Aliquot the cells from d into 50 μL / tube, wrap them in paper towels, and freeze them gradually at –70°C for storage.
[0072] (2) Yeast transformation of recombinant plasmids
[0073] a. Take 5 μL each of the sequencing-verified recombinant plasmids pESC-His-AmCASs, pESC-Ura-tHMG1 and pESCLeu-ERG7– and add them to 50 μL of yeast competent cells. Add 500 μL of Frozen-EZYeast Solution 3 and mix thoroughly.
[0074] b. Incubate in a 30℃ water bath for 45 minutes, vortexing 2-3 times every 15 minutes during this period;
[0075] c. Spread 100 μL of the above conversion mixture onto an SD-HLU plate and incubate upside down at 30°C for 2–4 days.
[0076] (3) Yeast plasmid extraction and PCR verification
[0077] a. Inoculate an appropriate number of positive clones into 10 mL of SD-HLU liquid medium and incubate at 30°C and 220 rpm for 24 h;
[0078] b. Take 4 mL of yeast culture, centrifuge at 8,000 rpm for 2 min to collect the cells, and discard or aspirate the culture medium.
[0079] c. Removal of yeast cell walls: Add 600 μL of enzyme digestion buffer, 1.2 μL of β-mercaptoethanol, and 50 μL of Snailase to every 20 mg of cell pellet, and incubate at 37°C for 3 h. Centrifuge at 5,000 rpm for 10 min, discard the supernatant, and collect the pellet; add 250 μL of Solution I to the cell pellet, and aspirate or shake until the cells are completely resuspended;
[0080] d. Add 250 μL Solution II, immediately and gently invert the centrifuge tube 5-10 times to mix, and let stand at room temperature for 2-4 minutes;
[0081] e. Add 350 μL Solution Ⅲ, immediately and gently invert the centrifuge tube 5-10 times to mix thoroughly, and centrifuge at 12,000 rpm for 10 min;
[0082] f. Carefully transfer all the supernatant into the adsorption column, let it stand at room temperature for 2 min, centrifuge at 8,000 rpm for 2 min, and discard the liquid in the collection tube;
[0083] g. Add 500 μL of Buffer DW1 to the adsorption column, incubate at 10,000 rpm for 1 min, and then discard the liquid in the collection tube;
[0084] h. Add 500 μL of Wash Solution to the adsorption column, inflate at 10,000 rpm for 1 min, then discard the liquid in the tube.
[0085] i. Place the adsorption column and empty collection tube into a centrifuge and centrifuge at 12,000 rpm for 2 min;
[0086] j. Place the adsorption column into a clean 1.5 mL centrifuge tube, add 50 μL of solution buffer to the center of the adsorption membrane, let stand at room temperature for 2 min, centrifuge at 10,000 rpm for 1 min, collect the yeast plasmid in the centrifuge tube, and the obtained plasmid DNA solution can be stored at -20℃.
[0087] k. Using extracted yeast plasmid DNA as a template, target genes were screened using universal primers for the vector and gene-specific primers, respectively. PCR reactions were performed according to the system in Table 6 to verify the success of the heterologous expression system construction.
[0088] Table 6: Yeast plasmid PCR reaction system
[0089] reagents Volume (μL) 2×EsTaqMix 5 Specific upstream primer 0.4 Downstream has universal primers 0.4 yeast plasmid DNA 4.2
[0090] PCR reaction conditions: 94℃ pre-denaturation for 2 min, 94℃ denaturation for 30 s, 55℃ annealing for 30 s, 72℃ extension for 30 s / kb, for 30 cycles. After the last cycle, incubate at 72℃ for 5 min to allow the reaction mixture to fully amplify, and store at 4℃.
[0091] 3. Functional verification of candidate triterpenoid cyclases in yeast
[0092] After PCR-verified positive transformants were activated and cultured on SD-HLU solid medium for 2 days, an appropriate amount was picked and seeded into 10 mL of SD-HLU medium and cultured at 30°C and 220 rpm for 24 h. Cells were collected by centrifugation at 1000×g for 6 min, washed twice with sterile water, and resuspended in SD-HLU medium to allow initial OD. 600 The culture was continued at 30℃ and 220 rpm for 5 days with a pH between 0.6 and 0.8. The cells were collected by centrifugation at 1000×g, washed with deionized water, and weighed. For each gram of wet weight of cells, 40 mL of 20% potassium hydroxide and 60 mL of 50% ethanol were added, and the mixture was thoroughly resuspended. The cells were then sonicated for 90 min to lyse the yeast cell wall. The lysate was extracted 3–4 times with n-hexane, the organic layer was evaporated to dryness under reduced pressure, and the residue was redissolved in n-hexane, filtered, and analyzed by GC-MS. The results are shown below. Figure 1 As shown. GC-MS analysis revealed that, compared to the control group, AmAS showed lower t... R One major product 1 was produced at 27.5 min, and at t R A small byproduct peak 2 was generated at 23.3 min, with molecular weights of 444 and 426, respectively.
[0093] Example 3: Preparation and structural identification of AmAS catalytic products
[0094] 1. Preparation of target products catalyzed by AmAS
[0095] The yeast engineered strain constructed in Example 2 was scaled up and fermented in 10L. After induction culture for 5 days according to the operation method in Example 2, the cells were collected by centrifugation. After alkaline lysis, hexane extraction and vacuum concentration, the residue was redissolved in ethyl acetate and separated by forward semi-preparative high performance liquid chromatography (hexane: ethyl acetate = 10:1, 4 mL / min). The fraction containing the target compound was detected by GC-MS. The main product arabidiol (1) was obtained by reversed-phase HPLC-UV (ACN, 1 mL / min, 203 nm) purification. A secondary product (2) was obtained by reversed-phase HPLC-UV (95% ACN, 1 mL / min, 203 nm) purification.
[0096] 2. Determination of the structure of the target product
[0097] All prepared compounds were dissolved in deuterated chloroform and subjected to NMR analysis. 1 H-NMR, 13 The structures of the compounds were resolved by C-NMR (Table 7). Based on existing literature reports, compound 1 is identified as the Malabaricane triterpenoid arabido. The NMR data of compound 2 are similar to those of compound 1, with the main difference being the absence of a methyl signal at C-27 and the presence of two additional olefin proton signals (δ¹⁸O). H =4.90,4.76), and finally the structure of compound 2 was determined by 2D-NMR to be (3S,13S)-malabarica-14(27),17,21-trien-3-ol.
[0098]
[0099] Table 7 Compounds 1 and 2 1 H and 13 C NMR data (δin ppm, Jin Hz)
[0100]
[0101]
[0102] 1 H(400MHz)and 13 C(100MHz)NMR data in chloroform-do overlapped signals.
[0103] Example 4: Key amino acids for AmAS function
[0104] 1. Multiple sequence alignment and site-directed mutagenesis
[0105] To identify the key amino acids for the catalytic activity of the cyclase AmAS, multiple sequence alignment of AmAS with functionally defined cyclases in plants was performed using ClustalW in MEGA7 software. Based on the alignment results, amino acid residues Q256, Y258, and IIH725-727 in AmAS were selected for further study. Seven sets of site-directed mutagenesis experiments were conducted using specific primers (Table 8).
[0106] Table 8. Design of site-directed mutagenesis-specific primers
[0107]
[0108]
[0109] Using overlap PCR, a plasmid containing wild-type AmAS was used as a template. Seven sets of specific primers were used for PCR amplification to obtain the target fragment. After PCR, the wild-type template was removed by digestion with the restriction enzyme DpnI to obtain the purified fragment. The fragment was ligated using a seamless ligation kit (Nanjing Novizan Co., Ltd.), and then transformed into E. coli DH-5α. Sequencing confirmed the positive clones (Table 9). The site-directed mutagenesis-positive recombinant plasmid was transformed into S. cerevisiae INVSc1 competent cells, with wild-type AmAS as a negative control. The successfully transformed mutant engineered bacteria were induced to express in 50 ml of solution (three parallel experiments). After 7 days of fermentation, the yeast cells were lysed in alkaline solution and extracted with n-hexane for GC-MS analysis. The results are shown in Table 9. Figure 2 As shown. Compared with the control group, the Q256L / W, Y258A / H, Q256W-Y258H, and IIH725-727VFM mutants produced trace amounts of the major product arabidiol, and no corresponding new product peaks appeared; in the IIH725-727VFN mutant, although the yield of arabidiol decreased by 45%, it was still the major product, and five new product peaks appeared. Comparison with the standard indicates that compound 3 is the known compound Lupeol.
[0110] Table 9. Plasmid composition of site-directed mutagenic yeast engineered bacteria
[0111]
[0112]
[0113] 2. Preparation and structural determination of AmAS-VFN mutant products
[0114] For the above mutant strain AmAS IIH-725-727VFN A 20L scale-up fermentation was performed. Compounds 4-7 were prepared using various separation instruments, and the results were analyzed by EI-MS (see figure). Figure 3 As shown), NMR ( 1 H-NMR, 13 C-NMR, DEPT135 1 H- 1The structures of compounds 4-7 were determined by H COSY, HSQC, HMBC and NOESY, optical rotation analysis and existing literature reports, respectively (3S,13R)-malabarica-14(27), 17,21-trien-3β-ol(4), (20E)-dammara-20(22), 24-dien-3β-ol(5), (3S,13S)-malabarica-17,21-dien-3β,14-diol(6) and (20R)-dammarenediol I(7) (Tables 10 and 11).
[0115] Table 10 1 H and 13 C NMR data of compounds 4and 6 (δin ppm, Jin Hz).
[0116]
[0117]
[0118] Table 11 1 H and 13 C NMR data of compounds 5and 7 (δin ppm, Jin Hz).
[0119]
[0120]
Claims
1. The use of a triterpenoid cyclase with the amino acid sequence shown in SEQ ID NO. 1 in the production of ailanthus-type 6-6-5 cyclic triterpenes, said ailanthus-type 6-6-5 cyclic triterpenes having the structure shown in Formula 1 or Formula 2:
